RAD101 met its Phase 2b primary endpoint, but cash runs out in Q4 2026 before Phase 3 can deliver data

Bull

A positive outcome sees the company initiate the multi-center, multi-country Phase 3 trial on schedule in Q4 2026, supported by the Siemens Healthineers supply agreement and a defined FDA regulatory pathway, demonstrating that the 93% MRI concordance result was sufficient to underpin a registrational design and that sufficient capital has been secured to sustain operations through enrollment. This would transform RAD101 from a proof-of-concept asset into a de-risked late-stage program with a credible path to NDA submission, substantially re-rating the stock.

Bear

The most likely failure mode is a capital shortfall: with a quarterly burn rate of approximately $14.9 million and cash that has required repeated dilutive raises at distressed prices, the company may be unable to fund Phase 3 startup costs before Q4 2026, forcing a delay or a partnership on unfavorable terms. A secondary risk is an inconclusive or extended FDA dialogue that prevents a clear registrational design from being locked, stalling trial initiation even if cash is technically available; the relatively small Phase 2b sample size (interim analysis of 14–20 patients) could also prompt FDA to request additional bridging data before approving the Phase 3 protocol.